Kelun-Biotech Will Present Updates for A166 at ASCO
Kelun-Biotech will attend the 2021 ASCO Annual Meeting from June 4-8. We will report the results from a Phase 1 study of A166 in Chinese patients with locally advanced or metastatic solid tumors (CTR20181301).
Link to Abstract:
Link to Poster:
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker. The study included 57 patients with a majority having high HER2 expressing solid tumors. No DLTs were observed in all dose groups. The ORR in the 4.8 and 6.0 mg/kg cohorts were 59.1% (13/22) and 71.4% (10/14), respectively. Median progression-free survival (PFS) was not reached, and one patient in the 4.8 mg/kg cohort has been on treatment for more than 19 months. A166 demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer. These results support the further development of A166 in clinical trials for the treatment of HER2+ solid tumors.
A166 is currently available for partnerships worldwide. Inquiries are welcome and may be directed to
Business Development, KLUS Pharma
Business Development, Kelun-Biotech
Thursday, May 20, 2021